[Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus].
To study a hypolipidemic action of alisat and lipostabil in patients with non-insulin-dependent diabetes mellitus (NIDDM). Changes in blood lipids were studied in 121 NIDDM patients aged 36-66 years with compensated or subcompensated carbohydrate metabolism on sugar-reducing therapy. The latter consisted of a 52-week course of alisat (600 mg/day) or lipostabil (900 mg/day) in baseline levels of total cholesterol (TC) under 6.5 mmol/l and above 6.5 mmol/l, respectively. Alisat and lipostal treatments reduced TC levels from 5.4 +/- 25 to 4.77 +/- 0.12 mmol/l and from 7.07 +/- 0.24 to 5.92 +/- 0.30, LDLP cholesterol from 4.0 +/- 0.31 to 2.98 +/- 0.15 mmol/l and 5.54 +/- 0.25 to 4.04 +/- 0.34 mmol/l, respectively. Lipostabil changed LDLP cholesterol and triglycerides from 0.51 +/- 0.05 to 0.33 +/- 0.03 mmol/l and from 2.54 +/- 0.25 to 1.66 +/- 0.15 mmol/l, respectively, while HDLP cholesterol rose from 1.22 +/- 0.10 to 1.55 +/- 0.07 mmol/l. Alisat did not change significantly. Adjuvant lipostabil is recommended in combined treatment of NIDDM in marked dyslipidemia, alisat--in moderate dyslipidemia.